<code id='8FB97CCCB4'></code><style id='8FB97CCCB4'></style>
    • <acronym id='8FB97CCCB4'></acronym>
      <center id='8FB97CCCB4'><center id='8FB97CCCB4'><tfoot id='8FB97CCCB4'></tfoot></center><abbr id='8FB97CCCB4'><dir id='8FB97CCCB4'><tfoot id='8FB97CCCB4'></tfoot><noframes id='8FB97CCCB4'>

    • <optgroup id='8FB97CCCB4'><strike id='8FB97CCCB4'><sup id='8FB97CCCB4'></sup></strike><code id='8FB97CCCB4'></code></optgroup>
        1. <b id='8FB97CCCB4'><label id='8FB97CCCB4'><select id='8FB97CCCB4'><dt id='8FB97CCCB4'><span id='8FB97CCCB4'></span></dt></select></label></b><u id='8FB97CCCB4'></u>
          <i id='8FB97CCCB4'><strike id='8FB97CCCB4'><tt id='8FB97CCCB4'><pre id='8FB97CCCB4'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:fashion    Page View:81

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In